(Total Views: 1076)
Posted On: 01/23/2021 4:11:50 PM
Post# of 154092
Leronlimab mentioned in this recent publication on HIV treatments:
"An excellent safety profile was also determined for the monoclonal antibody PRO140 (Leronlimab) [243]. Remarkably, this antibody has the potential to provide HIV-1-prophylaxis after a single subcutaneous injection a week and is currently further under investigation in a phase IIb and phase III study."
https://www.mdpi.com/2076-2607/9/2/228
https://www.mdpi.com/2076-2607/9/2/228/pdf
"An excellent safety profile was also determined for the monoclonal antibody PRO140 (Leronlimab) [243]. Remarkably, this antibody has the potential to provide HIV-1-prophylaxis after a single subcutaneous injection a week and is currently further under investigation in a phase IIb and phase III study."
https://www.mdpi.com/2076-2607/9/2/228
https://www.mdpi.com/2076-2607/9/2/228/pdf
(9)
(0)
